Amanta Healthcare Q2 FY27: Revenue Up 17%, Profit Up 26%, SteriPort Line 3 Operational
Amanta Healthcare reported Q2 FY27 revenue up 17% to ₹83.1 crore and PAT up 26% to ₹4.86 crore. SteriPort Line 3 is operational, increasing capacity by 75% to ₹11.6 crore annually. A 10.8 MW solar plant is operational, saving ₹9 crore annually. SVP capacity expansion is planned for Q1 FY28. The company targets 20%+ revenue CAGR and 25%+ EBITDA margins over two years.
The commissioning of SteriPort Line 3 represents a substantial capacity expansion (75%) and is expected to contribute significantly to revenue. The operational solar plant offers structural cost advantages and improves the ESG profile. The planned SVP expansion further diversifies and enhances the product portfolio. These strategic initiatives are expected to drive future growth and profitability.
The company reported strong year-on-year growth in revenue and profit, commissioned a new production line significantly increasing capacity, and initiated a solar power plant for cost savings and ESG benefits. The balance sheet has also been strengthened. These factors indicate positive operational and financial performance.
Amanta Healthcare Limited has announced its financial results for the second quarter and first half of FY27. The company reported a 17% year-on-year increase in revenue from operations for Q2 FY27, reaching ₹83.1 crore. EBITDA grew by approximately 22% to ₹18 crore, with an EBITDA margin of 21.6%. Profit After Tax (PAT) stood at ₹4.86 crore, marking a 26% year-on-year increase with a PAT margin of 6%.
For the first half of FY27 (ended September 2027), revenue was ₹151.9 crore, up 12% year-on-year. EBITDA for H1 FY27 was ₹33 crore with a margin of 22%, and PAT was ₹8.17 crore, a 12% increase.
The company highlighted significant operational achievements, including the commissioning of SteriPort Line 3 in September 2026, increasing its capacity by approximately 75% to ₹11.6 crore annually. This new line, featuring advanced automation and robotic operations, is expected to reach full ramp-up by mid-November 2026 and contribute about ₹60 crore to the top line in FY27.
Additionally, a 10.8 megawatt captive solar plant has been operational since the end of Q1 FY27, expected to provide annual power cost savings of ₹9 crore. The company has also strengthened its balance sheet, reducing its debt-to-equity ratio from 3.5x in FY23 to 1.1x in FY26.
Looking ahead, Amanta Healthcare is focusing on expanding its Small Volume Parenterals (SVP) capacity, with the new line expected to be operational by Q1 FY28, increasing capacity by 52% to approximately ₹31 crore. This expansion is primarily aimed at enhancing offerings for inhalation solutions and ophthalmics.
The company has set a 2-year target for revenue growth of over 20% CAGR and EBITDA margins of 25%+. Key milestones include the full ramp-up of SteriPort Line 3 and the commissioning of the expanded SVP facility in Q1 FY28.
What to do with a filing like this
Amanta Healthcare Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Amanta Healthcare Limited. Read the original for the full detail.